Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

AML: Erstmals klarer OS-Vorteil durch Erhaltungstherapie bei Patienten in Remission nachgewiesen

  • 8 Accesses

This is a preview of subscription content, log in to check access.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Author information

Correspondence to Dr. med. Nicola Siegmund-Schultze.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Siegmund-Schultze, N. AML: Erstmals klarer OS-Vorteil durch Erhaltungstherapie bei Patienten in Remission nachgewiesen. InFo Hämatol Onkol 23, 45–46 (2020). https://doi.org/10.1007/s15004-020-7994-7

Download citation